newsfilter
← Latest News
PR Newswire·

Liminal BioSciences Reports Second Quarter 2021 Financial Results

Receipt of FDA Approval for Ryplazim® (plasminogen, human-tvmh) Receipt of a Rare Pediatric Disease Priority Review Voucher Signature of Agreement to Divest Plasma-Derived Therapeutics Business to Kedrion Closing of the Sale of Plasma Collection